Harris & Harris Group Inc.

NEWS RELEASE

HARRIS & HARRIS GROUP, INC.	JANUARY 22, 2002
ONE ROCKEFELLER PLAZA
NEW YORK, NEW YORK 10020
NASDAQ/NMS SYMBOL: HHGP
CONTACT: MEL P. MELSHEIMER
TEL. NO. (212) 332-3614

HARRIS & HARRIS GROUP NOTES ANNOUNCEMENT OF NEUROMETRIX 510K APPROVAL

Harris & Harris Group, Inc. noted that, "NeuroMetrix, Inc. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its NC-stat nerve conduction testing system for the evaluation of lower extremity nerves.... The addition of lower extremity nerve measurements significantly expands the clinical utility of the NC-stat system to include the evaluation of common causes of low back pain, such as sciatica, as well as other neuromuscular conditions affecting the back and legs."

Harris & Harris Group owns approximately a 13.51 percent fully diluted interest in privately held NeuroMetrix.

Harris & Harris Group is a publicly traded venture capital company organized as a Business Development Company. Harris & Harris Group has 8,864,231 common shares issued and outstanding.

Detailed information about Harris & Harris Group and its holdings can also be found on its website at www.hhgp.com.

This press release may contain statements of a forward-looking nature relating to future events. Statements contained in this press release that are forward looking statements are intended to be made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc. undertakes no obligation to update or revise these forward looking statements to reflect new events or uncertainties.